Clinical trials: not yet recruiting
HIV-1 Infection
Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV
The goal of this clinical trial is to assess the effectiveness and safety of switching to bictegravir/lenacapavir (BIC/LEN) fixed-dose combination (FDC) compared with continuing stable baseline regimens (SBR) in virologically…
- Trial name
- ARTISTRY-3 (NCT07908446)
- Testing
- BIC/LEN FDC, Lenacapavir, SBR
- Volunteers
- 400 people
- Sponsor
- Gilead Sciences
HCC, Tace
Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with…
- Conditions
- HCC, Tace, Immunotherapy
- Trial name
- EXPECT (NCT07168668)
- Testing
- Transarterial chemoembolization, durvalumab and tremelimumab
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Stroke, Ischemic Stroke
Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning
Stroke is a leading global cause of death and disability. In 2021 there were 11.9 million incident strokes (10.7-13.2 million) and 93.8 million prevalent stroke survivors (89.0-99.3 million) worldwide.
- Conditions
- Stroke, Ischemic Stroke, Recurrent Stroke, Transient Ischemic Attack
- Trial name
- WISE (NCT07908303)
- Testing
- Huawei HAY20, AI agent dialogue
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Affiliated Hospital of Nantong University
Cheek Wrinkles, Midface Contour Deficiencies
A Study to Evaluate the Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies
This is a randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies.
- Trial name
- NCT07909421
- Testing
- GP0112, Juvéderm Voluma XC
- Where
- China
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Inguinal Hernia, Incarcerated Inguinal Hernia
Bassini Repair Versus Desarda Technique in Urgent Complicated Inguinal Hernia Repair
Inguinal hernias occur when abdominal contents, such as intestine or fat, protrude through a weakness in the lower abdominal wall.
- Conditions
- Inguinal Hernia, Incarcerated Inguinal Hernia, Strangulated Inguinal Hernia
- Trial name
- NCT07910240
- Testing
- Bassini Inguinal Herniorrhaphy, Desarda Inguinal Hernia Repair
- Volunteers
- 70 people
- Sponsor
- Assiut University
Lumbar Spondylosis
Comparative Effectiveness of Two Different Approaches to Radiofrequency Ablation of Lumbar Medial Branch Nerves
The purpose of this voluntary research study is to determine whether the parasagittal approach to lumbar medial branch (LMB) nerve radio frequency ablation (RFA) will have greater efficacy than the traditional approach to lumbar…
- Trial name
- LMB-RFA (NCT06283628)
- Testing
- Radiofrequency ablation of lumbar medial branch nerves.
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Skin Laxity, Localized Adiposity
Prospective Evaluation of Recombinant Pbserum Plus® and Pbserum HA 2.0® in Aesthetic and Regenerative Bioremodeling
This study will evaluate the efficacy and safety of recombinant enzymes contained in pbserum Plus® and pbserum HA 2.0® for aesthetic and regenerative tissue bioremodeling.
- Conditions
- Skin Laxity, Localized Adiposity, Cellulite, Tissue Fibrosis
- Trial name
- NCT07908953
- Testing
- Recombinant Hyaluronic Acid (pbserum HA 2.0®), pbserum Plus®
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Antony Barbosa Institute
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Little Lungs Study
This clinical trial is being done to evaluate the safety and clinical response of late surfactant treatment with budesonide in extremely preterm infants requiring mechanical ventilation at 7-14 days of age.
- Trial name
- NCT06855043
- Testing
- Calfactant, Budesonide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Acute Kidney Injury (AKI)
Precision-Medicine Diagnostic Support in Hospitalized Veterans With Acute Kidney Injury
Acute kidney injury (AKI) affects up to 20% of hospitalized Veterans and is strongly associated with morbidity and death. AKI is a diverse condition and timely and accurate diagnosis of the type of AKI is critical to begin…
- Trial name
- PRECISE-AKI (NCT07217808)
- Testing
- PRECISE-AKI Clinical Decision Support Tool
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- VA Office of Research and Development
Lung Cancer Screening
C-Raven LDCT: Lung Cancer Screening Intervention
This study is a three-arm, randomized controlled pilot of a lung cancer screening intervention. The investigators will recruit participants ages 50-80 who are likely to meet lung cancer screening guidelines.
- Trial name
- C-Raven LDCT (NCT07819318)
- Testing
- Video/Brochure, Video/Brochure/Follow-up Call
- Volunteers
- 300 people
- Sponsor
- Johns Hopkins University
Hepatitis B
B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants
This multi-country, longitudinal follow-up study will enrol adults with chronic hepatitis B (CHB) who previously participated in the Phase III B-Well-1 ((202009: NCT05630807) or B-Well-2 (219288: NCT05630820) studies, received 24…
- Trial name
- B-Ensure (NCT07908459)
- Testing
- Bepirovirsen
- Volunteers
- 303 people
- Sponsor
- GlaxoSmithKline
B Cell Lymphoma (BCL)
Multi-CAR-T Cells Targeting B Cell Lymphomas
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and…
- Trial name
- NCT04429438
- Testing
- 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Randomized, Phase 2
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.
- Conditions
- Randomized, Phase 2, Epcoritamab, Watch & Wait
- Trial name
- NCT07783594
- Testing
- Epcoritamab, Observation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Stroke, Ischemic Stroke
Detecting and Predicting Post-stroke Cognitive Impairment Using the Oxford Cognitive Screen
Cognitive problems are common after a stroke and must be identified early so that rehabilitation can be initiated to improve outcome.
- Conditions
- Stroke, Ischemic Stroke, Hemorrhagic Stroke, Intracerebral, Cognitive Dysfunction
- Trial name
- OCS-PRECISE (NCT07897916)
- Where
- 2 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- University of Copenhagen
Chronic Granulomatous Disease
Lentiviral Gene Therapy for CGD
This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene.
- Trial name
- NCT03645486
- Testing
- Infusion of lentiviral TYF-CGD-modified autologous stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Metachromatic Leukodystrophy (MLD)
Direct Lentiviral Injection Gene Therapy for MLD
This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to functionally correct the genetic defect.
- Trial name
- NCT03725670
- Testing
- Intrathecal and intravenous LV gene therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Obesity & Overweight
ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation
This randomized controlled trial aims to evaluate the efficacy and safety of Endoscopic Radial Compression Gastroplasty (ERCG) in mitigating weight regain following discontinuation of glucagon-like peptide-1 receptor agonists…
- Trial name
- NCT07908823
- Testing
- Endoscopic Radial Compression Gastroplasty (ERCG), Intensive Lifestyle Intervention (ILI)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Non-Small-Cell Lung Cancer
Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC
This is a multicenter, open-label, randomized phase III study in older or frail adults with unresectable stage III non-small cell lung cancer (NSCLC) who are considered unsuitable for concurrent chemoradiotherapy.
- Trial name
- NCT07908745
- Testing
- Reduced-Dose Thoracic Radiotherapy, Standard-Dose Thoracic Radiotherapy
- Volunteers
- 276 people
- Sponsor
- Ruijin Hospital
Diabetes (Insulin-requiring, Type 1 or Type 2)
Safety and Efficacy of the Fully Closed Loop iLet Bionic Pancreas in Adults With Type 1 and Type 2 Diabetes
The goal of this clinical trial is to evaluate the safety and efficacy of the fully closed loop (FCL) iLet automated insulin delivery (AID) System in people ≥18 years old with type 1 diabetes or type 2 diabetes requiring insulin…
- Trial name
- iLet FCL (NCT07911566)
- Testing
- iLet FCL
- Volunteers
- 400 people
- Sponsor
- Beta Bionics, Inc.
Canities, Grey Hair
Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)
Clinical Study to Assess the Safety and Efficacy of CS-002 (mTOR inhibitor) as a treatment for Canities (Grey Hair)
- Trial name
- NCT07166354
- Testing
- CS-002
- Volunteers
- 100 people
- Sponsor
- Applied Biology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.